~~<i id='D5B9E3B264'><strike id='D5B9E3B264'><tt id='D5B9E3B264'><pre id='D5B9E3B264'></pre></tt></strike></i>~~

Home» leisure time» knowledge

knowledge

author：Wikipedia 2025-09-05 15:29:05 Page View：372

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Liquid biopsy for lung cancer is launched by Delfi
Next article： Medical leaders decry Supreme Court decision on affirmative action

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

The future of health care in the House

AlexHogan/STATYou’rereadingthewebeditionofD.C.Diagnosis. Signuphere toreceivethisnewsletterinyourinb

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Why 40% Americans with Parkinson’s don’t see a neurologist

RichardHuckabee,seenwithhiswife,Angela,saysittooknineyearstobediagnosedwithParkinson’s.CourtesyRicha